key: cord-1008849-zgdfupfm
authors: McIlroy, James R.; Mullish, Benjamin H.; Goldenberg, Simon D.; Ianiro, Gianluca; Marchesi, Julian R.
title: Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, ‘COVID-19: Immunology and treatment options’, Felsenstein, Herbert McNamara et al. 2020′
date: 2020-07-12
journal: Clin Immunol
DOI: 10.1016/j.clim.2020.108542
sha: ea5ad09aab845e65b1463ee8c6111cb32bf8b864
doc_id: 1008849
cord_uid: zgdfupfm

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. To the Editor:

We read the focussed review authored by Felsenstein and colleagues with great interest and wish to add further perspective on a novel approach to immunotherapy in this patient population that has not previously been described.

In recent years several publications have demonstrated that a bidirectional dialogue exists between the host immune system and its resident hidden microbial majority, specifically the microbiome of the gut and other mucosal surfaces. Emerging evidence has led researchers to conclude that a gut-lung axis may exist and that perturbations of the gut microbiome can worsen outcomes in viral or bacterial animal models of respiratory infection 1 The available evidence appears to instil cautious optimism for the investigation of 

Microbiota regulates immune defense against respiratory tract influenza A virus infection

Gut microbiota may underlie the predisposition of healthy individuals to COVID-19

The mito-DAMP cardiolipin blocks IL-10 production causing persistent inflammation during bacterial pneumonia

Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis

Successful therapy of Clostridium difficile infection with fecal microbiota transplantation

Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease

Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota

Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut Published Online First: 03